uploads/2018/05/cells-1872666_1280.jpg

The Upside Potential in Editas Medicine Stock

By

Updated

Company overview

Editas Medicine (EDIT) is a clinical-stage genome-editing company focused on developing treatments for genetically defined diseases by correcting the genes that are causing them. 

Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals.

Article continues below advertisement

Analysts’ recommendations

Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.

Peers’ ratings

Of the total 16 analysts covering Alnylam Pharmaceuticals (ALNY) in May, 12 have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “sell” rating. The mean rating for the stock is 2.19, and its target price is $148.19.

Of the 13 analysts covering Ionis Pharmaceuticals (IONS) in May, four have given the stock “buy” or higher ratings, seven have given it “hold” ratings, and two have given it “sell” or lower ratings. The mean rating for the stock is 2.85, and its target price is $59.91.

Of the 23 analysts covering Amgen (AMGN) in May, 11 have given the stock “buy” or higher ratings, while 12 have given it “hold” ratings. The mean rating for the stock is 2.3, and its target price is $195.35.

In the next article, we’ll take a look at Editas Medicine’s research pipeline.

Advertisement

More From Market Realist